Kenya Medical Research Institute
Clinical Trials
22
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Therapeutic Efficacy Study of AL and DP in Western Kenya
- Conditions
- Malaria,Falciparum
- Interventions
- Drug: Dihydroartemisinin-piperaquine (DP)Drug: Artemether-lumefantrine (AL)
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Kenya Medical Research Institute
- Target Recruit Count
- 340
- Registration Number
- NCT05060198
Latent HIV-1, Viral Suppress and Hope for HIV Cure
- Conditions
- HIV-1-infection
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Kenya Medical Research Institute
- Target Recruit Count
- 222
- Registration Number
- NCT04938518
- Locations
- 🇰🇪
Kenya Medical Research Institute, Nairobi, Kenya
Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
- Conditions
- HPV-Related Carcinoma
- Interventions
- Drug: Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Kenya Medical Research Institute
- Target Recruit Count
- 135
- Registration Number
- NCT04920526
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
- Conditions
- HPV VaccineHPV InfectionHIV-1-infection
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Kenya Medical Research Institute
- Target Recruit Count
- 176
- Registration Number
- NCT04711265
- Locations
- 🇰🇪
Partners in Health Research and Development, Thika, Kiambu, Kenya
Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni
- Conditions
- Schistosoma Mansoni
- Interventions
- Dietary Supplement: Ujiplus®
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Kenya Medical Research Institute
- Target Recruit Count
- 400
- Registration Number
- NCT04679831
- Locations
- 🇰🇪
Mbita, Mbita, Kenya
- Prev
- 1
- 2
- 3
- Next
News
Novel Mango-Flavored Pill Shows Promise in Eradicating Intestinal Worms
A new mango-flavored pill combining two anti-parasitic drugs demonstrates promising results in clinical trials for treating intestinal worms.
KEMRI Advocates for Approval of Cabotegravir and Lenacapavir for HIV Prevention in Kenya
• Kenya Medical Research Institute (KEMRI) urges the government to approve Cabotegravir and Lenacapavir, two highly effective HIV prevention drugs, to reduce the nation's HIV burden. • Clinical trials show Cabotegravir, an injectable drug by GlaxoSmithKline, surpasses oral PrEP efficacy, while Lenacapavir, from Gilead Sciences, offers near 100% prevention with six-month injections. • Despite FDA and EMA approvals, Kenya's Pharmacy and Poisons Board has been slow to approve Cabotegravir, hindering access to advanced HIV prevention methods. • With 1.6 million Kenyans living with HIV/AIDS, KEMRI emphasizes that approving these drugs could significantly decrease new infections and save lives.
Tonix Pharmaceuticals and KEMRI Partner to Advance TNX-801 Mpox Vaccine
Tonix Pharmaceuticals collaborates with KEMRI to develop TNX-801, a live-virus vaccine, for mpox prevention.